Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

NIH 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 6 Fallopian Tube Neoplasms 6 Neoplasms 5 Neoplasm Metastasis 5 Carcinoma 4 Gastrointestinal Neoplasms 2 Breast Neoplasms 2 Stomach Neoplasms 1 Sarcoma 1 Renal Insufficiency 1 Rectal Neoplasms 1 Kidney Diseases 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Non-Small-Cell Lung 1 Advanced Solid Tumors 1 Advanced Hepatocellular Carcinoma 1

Interventions

Doxorubicin 33 pembrolizumab 16 Gemcitabine 15 eribulin 10 Irinotecan 10 olaratumab 9 Trabectedin 9 pazopanib 8 Docetaxel 8 Injections 7 Cyclophosphamide 7 Nivolumab 6 Fluorouracil 6 anlotinib 5 Temozolomide 5 Ipilimumab 5 Ifosfamide 5 Bevacizumab 5 tazemetostat 4 ridaforolimus 4 Drug Therapy 4 Cetuximab 4 Carboplatin 4 toripalimab 3 surufatinib 3 spartalizumab 3 ganitumab 3 entrectinib 3 conatumumab 3 belinostat 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Sarcoma × trebananib × Clear all

NCT01992341 2014-09-23

AMG 386 Drug-Drug Interaction Study With Paclitaxel

Amgen

Phase 1 Completed

Carcinoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡